Exploring the clinical significance of TPX2 in pancreatic cancer: from biomarker to immunotherapy
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-024-03628-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Zhengguang Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China. zhengguangzha…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Microtubule-Associated Proteins, Biomarkers, Tumor, Cell Cycle Proteins. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Youth Foundation of Nanjing University of Chinese Medicine, Medical Scientific Research Project of Jiangsu Provincial Health Commission.
Abstract (Originalsprache)
Pancreatic cancer (PC) is a highly aggressive malignancy characterized by a dismal prognosis. The present study is designed to elucidate the pivotal role of Xenopus kinesin-like protein 2 (TPX2) as a biomarker with substantial clinical prognostic significance in PC. By conducting a comprehensive analysis of RNA sequencing data and protein expression profiles obtained from multiple databases, we observed a pronounced upregulation of TPX2 expression in PC tissues compared to normal pancreatic tissues. Importantly, TPX2 emerged as an independent prognostic factor, demonstrating remarkable diagnostic accuracy. Notably, its expression levels were found to be significantly associated with the PC immune microenvironment and sensitivity to various therapeutic modalities. Functional assays revealed that the silencing of TPX2 markedly inhibited PC cell proliferation, metastasis, and the growth of subcutaneous tumors in PC mouse models. These effects were potentially mediated by the activation of CD8+ T cell immune responses and the inhibition of cell cycle progression and adhesion mechanisms. Taken together, our findings indicate that TPX2 may serve as a critical biomarker for the diagnosis and clinical management of patients with PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Laboratory, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China. zhengguangzhang@njucm.edu.cn.
- School of Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China. zhengguangzhang@njucm.edu.cn.
- School of Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China.
- Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China.
- Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China. fsyy00340@njucm.edu.cn.
- Jiangsu Key Laboratory of Children's Health and Chinese Medicine, Institute of Pediatrics, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. cunsishen@126.com.
Förderung
- National Natural Science Foundation of China
- Natural Science Youth Foundation of Nanjing University of Chinese Medicine
- Medical Scientific Research Project of Jiangsu Provincial Health Commission
- Nanjing Medical Science and technique Development Foundation
- Traditional Chinese Medicine Youth Talent Training Program of Nanjing
- Outstanding Youth Fund Project of Nanjing Health Science and Technology Development
- Construction Project of Nanjing Key Laboratory of Chinese Medicine Preparation and Clinical Pharmacy
Zitieren
APA
Zhang, Z., Liu, Z., Yao, Y., Li, M., Shen, C., & Zhou, F. (2025). Exploring the clinical significance of TPX2 in pancreatic cancer: from biomarker to immunotherapy. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03628-0
Vancouver
Zhang Z, Liu Z, Yao Y, Li M, Shen C, Zhou F. Exploring the clinical significance of TPX2 in pancreatic cancer: from biomarker to immunotherapy. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03628-0
BibTeX
@article{Zhang2025,
author = {Zhang, Zhengguang and Liu, Zixian and Yao, Ying and Li, Min and Shen, Cunsi and Zhou, Fuqiong},
title = {Exploring the clinical significance of TPX2 in pancreatic cancer: from biomarker to immunotherapy},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-024-03628-0}
}
EUVIMED